Table 2.

The association between standardized log2-transformed plasma Aβ40 and Aβ42 levels with risk of cancer.

Cancer
Model IModel II
Plasma assessment (pg/mL)an/NHR (95% CI)HR (95% CI)
Aβ40
Per SD increase560/3,9491.13 (1.03–1.24)1.12 (1.02–1.23)
Quartiles (range)
 1st quartile (−8.05 to −0.61)126/9881.001.00
 2nd quartile (−0.61 to −0.01)138/9871.10 (0.86–1.40)1.11 (0.87–1.42)
 3rd quartile (−0.01 to 0.59)136/9871.12 (0.87–1.43)1.13 (0.88–1.44)
 4th quartile (0.59–4.24)160/9871.47 (1.14–1.88)1.43 (1.11–1.83)
Ptrend.004.005
Aβ42
Per SD increase560/3,9491.12 (1.03–1.23)1.12 (1.03–1.23)
Quartiles (range)
 1st quartile (−11.4 to −0.53)124/9881.001.00
 2nd quartile (−0.53 to 0.03)136/9871.11 (0.87–1.42)1.13 (0.88–1.44)
 3rd quartile (0.03–0.59)140/9871.14 (0.89–1.45)1.16 (0.91–1.47)
 4th quartile (0.59–8.46)160/9871.38 (1.09–1.75)1.38 (1.09–1.76)
Ptrend.009.009
  • Note: HRs in model I are adjusted for age at blood draw, sex, and assay batch number. HRs in model II are adjusted for covariates in model I plus adjustment for education, body mass index, hypertension, hypercholesterolemia, diabetes mellitus, smoking, alcohol use, CES-D sum score, and systemic immune-inflammation index.

  • Abbreviations: n, number of participants with incident cancer; N, total number for participants.

  • aPlasma assessments are log2 transformed and standardized.